Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03622-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Nasr Alrabadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan. nnalrabadi@just.ed…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiovascular Agents, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Many atrial fibrillation (AF) patients use cardiovascular medications for indications other than AF. These medications can affect morbidity and mortality. We aim to investigate the characteristics of AF patients who use different medication classes and their clinical course. METHODS: We collected data from the prospective, multicenter registry, JoFib study. We identified classes of non-AF medications (medications not used for rate control, rhythm control, or anticoagulation), described demographic and clinical characteristics, and investigated AF-related outcomes according to these medication classes. RESULTS: From a total of 2020 patients, five classes of cardiovascular non-AF medications were identified, aspirin, P2Y12 inhibitors, ACE inhibitors/ARBs, statins, and diuretics. The most commonly used non-AF medications were diuretics and ACE inhibitors/ARBs (39.2%, and 39%, respectively). 51% of AF patients took more than one non-AF medication. Multivariable Cox regression analysis demonstrated that ACE inhibitor/ARB therapy independently reduced the risks of all-cause mortality and cardiovascular mortality (aHR 0.50, 95%CI 0.37-0.68; aHR 0.51, 95%CI 0.34-0.75, respectively) and that statin therapy reduced the risk of cardiovascular mortality (aHR 0.68, 95%CI 0.48-0.98) in AF patients. Multivariable logistic regression analysis demonstrated a protective effect of statin therapy against the secondary outcome, clinically relevant non-major bleeding (CRNMB) (adjusted OR 0.62 95%CI 0.42-0.94). CONCLUSION: Our findings suggest a protective effect of ACE inhibitors/ARBs against all-cause and cardiovascular mortality, statins against cardiovascular mortality, and CRNMB in patients with AF. Accordingly, these medications should be encouraged in patients with AF when indicated. Additionally, future research should explore whether these medications should be offered to AF patients more routinely. The study was registered with Clinicaltrials.gov (unique identifier number: NCT03917992, Registration date:14/4/2019).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan. nnalrabadi@just.edu.jo.
- Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
- Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
- Department of Cardiology, Istishari Hospital, Amman, Jordan.
Zitieren
APA
Alrabadi, N., Al-Nusair, M., Haddad, R., Alburie, L., Mhaidat, N., Aljarrah, M., & Hamoudeh, A. (2024). Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03622-8
Vancouver
Alrabadi N, Al-Nusair M, Haddad R, Alburie L, Mhaidat N, Aljarrah M, et al. Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03622-8
BibTeX
@article{Alrabadi2024,
author = {Alrabadi, Nasr and Al-Nusair, Mohammed and Haddad, Razan and Alburie, Lama and Mhaidat, Nizar and Aljarrah, Mohamad and Hamoudeh, Ayman},
title = {Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03622-8}
}
EUVIMED